ASCO 2021: 摘要概览与展望 2

时间:2021-05-23 20:01:43   热度:37.1℃   作者:网络

<a href='https://www.medsci.cn/search?q=ASCO'>ASCO</a> Annual Meetings | Cancer.Net

 

对于肿瘤学学术进展随者来说,Asco摘要的发布是一年中最大的事件之一,尽管连续第二年进行虚拟化,但2021年看起来仍将提供重要更新的一部分。梅斯医学将带领大家了解最近进展~ENJOY!

然而,许多最重要的数据仍处于保密状态,最新的摘要将于6月3日美国东部时间下午5点(会议召开的前一天)发布。

重要的Asco最新摘要节选

 

重点关注的Asco最新摘要结果预告节选1:

阿斯利康/默沙东Lynparza(利普卓)(Merck&Co Lynparza Olympia):PH(3)辅助化疗后,Lynparza在种系BRCA1 / 2突变和高风险HER2阴性早期乳腺癌中进行(新)辅助化疗后的试验 默沙东Keynote-564:Keytruda作为肾切除术后辅助治疗肾细胞癌的ph3试验 诺华177Lu-PSMA-617:177Lu-PSMA-617在转移性去势抵抗性前列腺癌中的第3期临床试验 君实生物和Coherus Biosciences 拓益Jupiter-02:拓益(toripalimab)联合化学治疗复发或转移性鼻咽癌的一线治疗的ph3试验 BMS Opdivo和Yervoy Checkmate-648:Opdivo加Yervoy等化学疗法作为晚期食道鳞状细胞癌的一线治疗CheckMate 648研究的第一项结果。重要精选摘要目录:
重要精选摘要目录
公司 项目 药物作用机制 摘要序列号 题目概述
Adaptimmune Afami-cel Anti-Mage-A4 eTCR 11504 Adaptimmune’s T-cell receptors see a route to market
Alkermes Nemvaleukin IL-2 mimic 2513 Responses seen in monotherapy and with Keytruda across various tumours 
Allogene ALLO-501 Anti-CD19 allo Car-T 2529 Off-the-shelf cell therapy inches towards reality
Alpine Immune ALPN-202 Conditional CD28 costimulator and dual checkpoint inhibitor 2547 Ph1 dose escalation; 1 unconfirmed PR and 5 SD in 11 subjects
Arcus Etrumadenant + zimberelimab + AB680 A2aR/A2bR antagonist + anti-PD-1 + anti-CD73 5039 In evaluable pts, PSA response 5/14, radiographic response 3/8, with 1 CR, composite response rate was 43% (6/14)
Black Diamond BDTX-189  EGFR/HER2 kinase inhibitor 3086 Of 15 evaluable, 1 confirmed PR, 3 SD and 10 progressive disease
Bristol Myers Squibb Relatlimab Anti-Lag3 MAb 9503 Bristol’s Lag3 case for a replacement for Yervoy
Cullinan CLN-081 EGFR Exon20 inhibitor 9077 Of 25 evaluable, 10 PRs, 14 SD, 1 progressive disease. Later cut to be presented
G1 Rintodestrant  SERD 1063 Ph1 safety data: rintodestrant-related AEs in 8%, all grade 2
I-Mab Uliledlimab Anti-CD73 MAb 2511 Of 13 evaluable, 3 CRs or PRs (ORR 23%) and 3 SD (disease control rate 46%).
Immunogen Mirvetuximab Anti-FRα ADC 5504 Of 33 pts with high FRα expression ORR 64%, mDOR of 11.8 months, and mPFS of 10.6 months (Forward I study failed in all-comers)
Immutep eftilagimod alpha Lag3  9046; 6028; 2518  Data from ongoing Ph2 trials in combination with Keytruda (NSCLC & H&N), and Ph1 plus Bavencio.  
Kadmon KD033  Anti-PD-L1/IL-15 fusion protein  2568 Of 6 evaluable, 1 SD
Macrogenics MGC018  Anti-B7-H3 ADC 2631 3 unconfirmed PRs in melanoma pts
Merus Zenocutuzumab Anti-Her2/Her3 bispecific 3003 Merus intrigues in pancreatic cancer
Roche Tecentriq Anti-PD-L1 MAb 8500 Adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers
SQZ Biotechnologies SQZ-PBMC-HPV-101 

T-cell surface glycoprotein CD8 stimulant

2536 4 SD in 10 evaluable pts 
Sutro STRO-002  FRα inhibitor 5550 Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR. Disease control rate was 74% at 12 weeks and 61% at 16 weeks. 
Sensei  SNS-301 ASPH targeted bacteriophage  6029 67% response rate in 12 PD-1 refractory H&N patients 
PDS Biotech PDS0101 HPV targeted T cell activator  2501 In combination with M9241 and bintrafusp alpha, ORR of 71%

当然,这还远远没有详尽地介绍重要的口头演讲,并且在接下来的几周内将有更多的数据发布,尽请保持关注!

更多内容关注梅斯医学ASCO专题页:https://meeting.medsci.cn/ASCO2020

参考来源:https://meetinglibrary.asco.org/results?meetingView=2021%20ASCO%20Annual%20Meeting

 

上一篇: Br J Cancer:多吃水果和蔬菜能...

下一篇: 痴呆症治疗瓶颈如何突破?两大研究带来新启...


 本站广告